{
    "clinical_study": {
        "@rank": "82405", 
        "arm_group": [
            {
                "arm_group_label": "Secukinumab", 
                "arm_group_type": "Experimental", 
                "description": "Secukinumab will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the safety and efficacy of secukinumab on the preservation of\n      pancreatic beta cells in patients with newly-diagnosed type 1 diabetes mellitus."
        }, 
        "brief_title": "Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus", 
        "completion_date": {
            "#text": "April 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 1 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Males and females aged 18-35 years initially (subjects aged 8-17 may be included at a\n        later stage, starting with age 12-17 years, followed by age 8-11 years).\n\n        Body weight between 40-120 kg initially (subjects weighing 21-39 kg may be included at a\n        later stage).\n\n        Recent onset type 1 diabetes mellitus, diagnosed with 100 days of first dose. Peak\n        stimulated C-peptide levels >/= 0.2 pmol/L following mixed meal tolerance test\n\n        Exclusion Criteria:\n\n        Any form of diabetes other than auto-immune type 1 (eg, type 2 diabetes, maturity onset\n        diabetes of the young, latent autoimmune diabetes of the adult).\n\n        Diabetic ketoacidosis within 2 weeks of screening. Pregnancy or lactation. Recent (within\n        2 weeks of screening), ongoing, chronic or recurrent infectious disease.\n\n        Active infection with hepatitis B or C, Epstein-Barr virus, cytomegalovirus, or HIV.\n\n        Tuberculosis infection. Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "35 Years", 
            "minimum_age": "8 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044848", 
            "org_study_id": "CAIN457A2227"
        }, 
        "intervention": [
            {
                "arm_group_label": "Secukinumab", 
                "intervention_name": "Secukinumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "type 1 diabetes mellitus", 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Peter Gottlieb"
                }, 
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "MS B140"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Desmond Schatz"
                }, 
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32610"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Henry Rodriguez"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Bruce Bode"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30309"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Mark Rigby"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Antoinette Moran"
                }, 
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55455"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64108"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Robin Goland"
                }, 
                "facility": {
                    "address": {
                        "city": "New York City", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Steven Willi"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104-4399"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "William Russell"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232-8160"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Philip Raskin"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390-9034"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "William Hagopian", 
                    "phone": "206-568-1485"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98122"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Carla Greenbaum"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98101"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaulkee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53215"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus(T1D)", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Amount of C-peptide (a protein that shows how much insulin the body is producing) released in 2 hours during a mixed meal tolerance test. The result of the test performed at screening will be compared against that performed at 52 weeks after the start of treatment.", 
                "measure": "Stimulated C-peptide in response to a standard mixed meal tolerance test", 
                "safety_issue": "No", 
                "time_frame": "Week 52"
            }, 
            {
                "description": "Monitoring of adverse events and serious adverse events on all patients participating in the study.", 
                "measure": "Number of patients with adverse events and serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044848"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Total daily dose of insulin will be monitored with the use of a diary of 7 days prior to each study visit.", 
                "measure": "Total daily dose of insulin", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "HbA1c levels will be monitored at baseline, day 29, weeks 8, 12, 24, 36, and 52, and months 15, 18, 24, 30, and 36 after the start of dosing.", 
                "measure": "Overall blood glucose control (HbA1c levels)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "The number of hypoglycemic events, especially serious and/or severe ones will be monitored via safety reporting and diary cards ( 7 days before each study visit).", 
                "measure": "Number of hypoglycemic events", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "description": "In the event an effect is detected at the end of the 1 year treatment period, evaluation of the durability of effect on the amount of C-peptide (a protein that shows how much insulin the body is producing) released in 2 hours during a mixed meal tolerance test once the treatment period is over. The result of the test performed at screening will be compared against that performed at 52 weeks after the start of treatment, and at the following times during the up to 2 year follow-up period: 15, 18, 24, 30, and 36 months after the start of treatment.", 
                "measure": "Durability of the effect on stimulated C-peptide in response to a mixed meal tolerance test", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}